The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan

Summary

This is a multi-center, non-randomized, open-label, parallel group, multiple-dose study to assess the pharmacokinetic, safety, and tolerability of balovaptan in male and female subjects with moderate hepatic impairment compared to healthy subjects with normal hepatic function matched by age (±10 years), sex, and body mass index (BMI; ±20%).

Timeline

Start

2022-06-26

Primary completion

2022-09-24

Completion

2022-10-13

Drugs

Indications